4507:TYO
Shionogi & Co Ltd
¥2,825.00
arrow_upward
+0.21%(+6.00) 1D
Aug 14, 10:12:20 AM GMT+9 · JPY
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
¥2,848
High
¥2,850
Low
¥2,810
Mkt. cap
2.51T
Avg. vol.
2.77M
Volume
898.10K
Dividend
2.51%
Quarterly dividend
¥18
Ex-dividend date
Sep 29, 2025
P/E ratio
9.12
52-wk high
¥3,758
52-wk low
¥2,392
EPS
¥310
Shares outstanding
314.50M
No. of employees
6K
Open
¥2,848
High
¥2,850
Low
¥2,810
Mkt. cap
2.51T
Avg. vol.
2.77M
Volume
898.10K
Dividend
2.51%
Quarterly dividend
¥18
Ex-dividend date
Sep 29, 2025
P/E ratio
9.12
52-wk high
¥3,758
52-wk low
¥2,392
EPS
¥310
Shares outstanding
314.50M
No. of employees
6K
News stories
From web sources and news partners
Simply Wall Street
·
2 days ago
How Shionogi’s Q1 2026 Earnings Jump and U.S. XOCOVA Launch Will Impact Shionogi (TSE:4507) Investors
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6.22K
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com
Last report
Aug 3, 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
163.31B / 158.67B
Fiscal Q1 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in JPY | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 113.18B | 147.72B | 138.99B | 163.31B |
Cost of goods sold | 16.94B | 25.09B | 28.10B | 30.80B |
Cost of revenue | 16.94B | 25.09B | 28.10B | 30.80B |
Research and development expenses | 27.55B | 29.87B | 40.54B | 31.79B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 27.56B | 35.27B | 32.92B | 44.36B |
Operating expense | 56.57B | 48.45B | 100.06B | 113.87B |
Total operating expenses | 73.51B | 73.54B | 128.17B | 144.66B |
Operating income | 39.67B | 74.18B | 10.83B | 18.64B |
Other non operating income | - | -1.00M | 7.31B | -2.00M |
EBT including unusual items | 52.06B | 92.89B | 47.64B | 73.74B |
EBT excluding unusual items | 52.06B | 93.10B | 47.80B | 25.47B |
Income tax expense | 7.87B | 18.21B | -56.00M | -23.98B |
Effective tax rate | 15.12% | 19.60% | -0.12% | -32.52% |
Other operating expenses | 979.00M | -17.25B | 15.44B | 21.90B |
Net income | 44.19B | 74.68B | 46.93B | 97.70B |
Net profit margin | 39.04% | 50.56% | 33.77% | 59.82% |
Earnings per share | - | - | - | - |
Interest and investment income | 14.21B | 20.53B | 23.73B | 12.15B |
Interest expense | -1.82B | -1.61B | - | -5.32B |
Net interest expenses | 12.38B | 18.92B | 23.73B | 6.82B |
Depreciation and amortization charges | -485.00M | - | -1.53B | - |
EBITDA | 44.83B | 80.21B | 21.59B | 39.52B |
Gain or loss from assets sale | - | - | 35.04B | - |
AI content may include mistakes. Learn more